Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences .
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Covidful (Chinese: 科维福; pinyin: Kēwéifú) |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
|
In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[2]
In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[3]
On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]